Tsingke Biotech Hosts 2025 Small Nucleic Acid Therapeutics Roundtable in Beijing

Industry experts gather to explore oligonucleotide innovation, delivery strategies, and commercialization pathways

BEIJING, July 29, 2025 /PRNewswire/ -- Tsingke Biotech, a leading provider of synthetic biology and nucleic acid solutions, successfully hosted the 2025 Small Nucleic Acid Therapeutics Roundtable on July 26 in Beijing. The event convened over 100 leading scientists, biotech executives, and R&D decision-makers to discuss key advances in oligonucleotide drug development, including synthesis, delivery technologies, and industrial translation.

The forum featured keynote presentations and a high-level panel discussion addressing the critical challenges and opportunities shaping the future of RNA-based therapeutics. Topics included non-hepatic targeting strategies, aptamer screening, CMC compliance, IP strategies, and next-generation delivery platforms.

"Oligonucleotide therapeutics are entering a decisive phase, where delivery, manufacturability, and regulatory readiness are just as important as molecular design," said a Tsingke Biotech spokesperson. "This roundtable reflects our commitment to supporting the entire innovation-to-industrialization pipeline through advanced synthesis and platform capabilities."

Key Highlights from the Roundtable:

- Structural Innovation & Delivery Systems: Experts shared recent progress in nucleic acid design and the development of circular and condensed structures to improve stability and tissue distribution.
- Non-Hepatic and CNS Targeting: New delivery strategies based on glycosylated carriers and ring-shaped condensation mechanisms demonstrated promise in crossing physiological barriers such as the blood-brain barrier.
- Aptamer Drug Development: Screening methods combining solid–liquid interface selection and fluorescence-based validation were discussed as efficient tools for identifying high-affinity aptamer candidates.
- Panel Discussion: Leading voices in the industry addressed pressing issues including:

• China's gap in delivery platform technology and core patents
• The importance of early-stage CMC planning and platform construction
• Navigating cost barriers, clinical acceptance, and IP risk in the domestic ecosystem
• The future role of enzymatic synthesis and cell-free manufacturing

Tsingke's Role: Enabling Innovation Through Scalable Manufacturing

As the host and initiator of this roundtable, Tsingke Biotech shared its latest progress in high-purity oligonucleotide synthesis, chemical modification, and IND-enabling raw material support. The company emphasized its commitment to enabling faster and more reliable translation of RNA therapeutics from lab to clinic through robust production capabilities and collaborative partnerships.

"The next decade will define the role of oligonucleotides in precision medicine," the spokesperson added. "Tsingke will continue to serve as a connector between innovation and application, empowering therapeutic developers worldwide."

For more information about Tsingke's nucleic acid synthesis services, visit www.tsingke.com

About Tsingke Biotech

Tsingke Biotech is a synthetic biology and biotech manufacturing company focused on gene and nucleic acid technologies. The company provides a wide portfolio of services including gene synthesis, oligonucleotide production, RNA therapeutics support, and GMP-compliant raw material manufacturing for research, diagnostics, and drug development applications.

Photo - https://mma.prnewswire.com/media/2739859/image.jpg